Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials

ConclusionsIn both EM and CM, treatment with erenumab is associated with a significant and sustained reduction in the use of acute headache medication, in particular MSM.Trial registrationsNCT02456740; NCT02066415; NCT02174861.

http://link.springer.com/10.1186/s10194-021-01292-w

Source: The Journal of Headache and Pain - July 23, 2021 Category: Neurology Source Type: research